Nasdaq에 대한 매도 수량은 투자자에게 Nasdaq의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Nasdaq (NASDAQ:NDAQ) 주식, 공매도 수량 보고

Nasdaq

Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.

News

Politics

Markets

NDAQ

주요 미국 주식 시장은 전 대통령인 지미 카터의 삶과 유산을 기리기 위해 1월 9일에 문을 닫을 예정이다. 카터는 일요일에 100세로 세상을 떠났다. 무슨 일이 있었나: 인터컨티넨탈 익스체인지(NYSE:ICE)가 소유한 뉴욕 증권 거래소는 조 바이든 대통령이 카터 추모의 날(National Day of Mourning)을 선포한 것에 따라 1월 9일에 시장을 폐쇄할 것이라고 월요일 확인했다.

미국 시장은 지미 카터 대통령의 국가 장례식을 위해 폐장 예정: 알아야 할 사항

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

$DOGE

ADDYY

HEINY

LULU

RBLX

VWAGY

밈 암호화폐인 도지코인(CRYPTO: DOGE)은 지난 한 주 동안 80% 이상 상승하며 52주 신고가를 경신하는 등 가격과 가치가 급등하고 있다.
최근의 가치 상승으로 도지코인은 일부 유명 글로벌 기업의 가치를 넘어섰다.

급등한 도지코인: 포드, 아디다스, 룰루레몬, 로블록스 등 15개 기업보다 시가총액 높아

Earnings

Pre-Market Outlook

Trading Ideas

월요일 아침 (현지 시간 기준) 미국 주식 선물이 상승하면서 오늘 투자자의 관심을 끌 수 있는 일부 주식은 다음과 같다: 월스트리트는 맥도날드(NYSE:MCD)가 개장 전에 분기 이익을 주당 3.07달러, 매출 66억 1천만 달러로 보고할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면 맥도날드 주가는 시간외 거래에서 0.3% 하락한 251.18달러를 기록했다.

월요일 주목해야 할 주식: 맥도날드, 나스닥, 온 세미컨덕터 그리고 2종목

Nasdaq Inc

<ul>
<li>Portugal's 4th largest bank expands Nasdaq partnership, adopting Calypso's Front Office and Risk platform</li>
<li>Fully integrated system will be deployed in the cloud to enhance flexibility and scalability of novobanco's treasury infrastructure</li>
</ul>

Novobanco Expands Nasdaq Calypso Partnership To Streamline Capital Market Operations

Oppenheimer analyst Owen Lau maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $86 to $89.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on Nasdaq, Raises Price Target to $89

Barclays analyst Benjamin Budish maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Overweight and lowers the price target from $97 to $96.

Barclays Maintains Overweight on Nasdaq, Lowers Price Target to $96

Citigroup analyst Christopher Allen maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and raises the price target from $78 to $84.

Citigroup Maintains Neutral on Nasdaq, Raises Price Target to $84

RBC Capital analyst Ashish Sabadra reiterates Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and maintains $95 price target.

Reiteration

RBC Capital Reiterates Outperform on Nasdaq, Maintains $95 Price Target

The stock market is closed on Thursday, Jan. 9, 2025 for a National Day of Mourning to honor former President Jimmy Carter whose state funeral will be held at Washington National Cathedral <a href="https://www.benzinga.com/24/12/42725647/markets-will-close-for-president-jimmy-carters-state-funeral-what-you-need-to-know">at 10 a.m. ET.&nbsp;</a>
The Details: The New York Stock Exchange, owned by Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), and the Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) have suspended trading in equities and options on Thursday and will resume regular trading hours on Friday.&nbsp;
Lynn Martin, president of NYSE Group, praised Carter's humble roots and life of public service <a href="https://www.benzinga.com/markets/24/12/42717748/will-markets-be-closed-for-former-president-jimmy-carters-funeral-heres-what-investors-should-know">in a statement</a> announcing the closure of the markets.
&#8220;During his noteworthy post-presidential life, President Carter left an enduring legacy of humanitarianism. The NYSE will respectfully honor President Carter&#8217;s lifetime of service to our nation by closing our markets on the National Day of Mourning,&#8221; Martin said.&nbsp;
Read More: <a href="https://www.benzinga.com/25/01/42768507/china-slaps-export-restrictions-on-dozens-of-us-companies-boeing-lockheed-martin-general-dynamics-raytheon-affected">China&#8217;s Export Crackdown Hits Boeing, Lockheed Martin And More&nbsp;</a>
Tal Cohen, president of Nasdaq, also released <a href="https://www.benzinga.com/pressreleases/24/12/g42723458/nasdaq-announces-the-closure-of-its-u-s-markets-in-honor-of-a-national-day-of-mourning-for-former-">a statement </a>announcing the closure of all Nasdaq markets.&nbsp;
&#8220;President Carter was an exemplary leader, one who tirelessly continued his efforts to improve the human condition even after his tenure in public office was complete. His contributions will be felt by those around the world for years to come. On behalf of Nasdaq, we extend our deepest condolences to the Carter Family,&#8221; Cohen said.&nbsp;
Cohen <a href="https://www.npr.org/2025/01/09/nx-s1-5251459/u-s-stock-markets-close-mourning-former-president-jimmy-carter">told</a> NPR the financial industry came together to honor Carter's legacy of service.&nbsp;
&#8220;It was a large undertaking,&#8221; Cohen said. &#8220;But we thought it was worth the effort.&#8221;
Thursday's market closures continue a Wall Street tradition dating back to 1865 of closing markets in order to honor deceased presidents. The most recent closure was in 2018 following the death of former President George H.W. Bush.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/01/42854890/us-records-first-human-bird-flu-death-high-levels-of-respiratory-illnesses-vaccine-stocks-rally">US Records First Human Bird Flu Death, High Levels Of Respiratory Illnesses: Vaccine Stocks Rally </a></li>
</ul>
Photo: Shutterstock

Equities

Options

Is The Stock Market Closed For Jimmy Carter's State Funeral?

Raymond James analyst Patrick O'Shaughnessy maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $83 to $84.

Raymond James Maintains Outperform on Nasdaq, Raises Price Target to $84

In the preceding three months, 14 analysts have released ratings for Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $87.71, a high estimate of $98.00, and a low estimate of $80.00. Witnessing a positive shift, the current average has risen by 4.7% from the previous average price target of $83.77.
<img src="https://www.benzinga.com/files/images/story/2025/1736359224_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nasdaq. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Nasdaq. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Nasdaq's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Nasdaq's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Delving into Nasdaq's Background</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Nasdaq's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Nasdaq displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 31.08%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Nasdaq's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nasdaq's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.79%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Nasdaq's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a high debt-to-equity ratio of 0.93, Nasdaq faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Nasdaq: Insights From 14 Analyst Reviews

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler analyst Clarke Jeffries upgraded the rating for Autodesk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADSK#NASDAQ">ADSK</a>) from Neutral to Overweight and raised the price target from $311 to $357. Autodesk shares closed at $290.82 on Tuesday. <a href="https://www.benzinga.com/quote/ADSK/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Brian Bedell upgraded Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) from Hold to Buy and raised the price target from $80 to $98. Nasdaq shares closed at $76.36 on Tuesday. <a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst John Lovallo upgraded the rating for PulteGroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) from Neutral to Buy but lowered the price target from $154 to $148. PulteGroup shares closed at $107.83 on Monday. <a href="https://www.benzinga.com/quote/PHM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Michael Sison upgraded RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) from Equal-Weight to Overweight and raised the price target from $134 to $140. RPM shares closed at $121.74 on Tuesday. <a href="https://www.benzinga.com/quote/RPM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Mizuho analyst Siti Panigrahi upgraded Twilio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) from Neutral to Outperform and raised the price target from $85 to $140. Twilio shares closed at $109.82 on Tuesday. <a href="https://www.benzinga.com/quote/TWLO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NDAQ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-1024x578.png" alt="" class="wp-image-723783" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/08070637/image-44.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42846607/bank-of-new-york-mellon-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Bank of New York Mellon Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a></li>
</ul>

Upgrades

ADSK

TWLO

This Nasdaq Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Deutsche Bank analyst Brian Bedell upgrades Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) from Hold to Buy and raises the price target from $80 to $98.

Deutsche Bank Upgrades Nasdaq to Buy, Raises Price Target to $98

Major U.S. stock markets are set to close Jan. 9 to honor the life and legacy of former President Jimmy Carter, who died at the <a href="https://www.benzinga.com/movers-shakers/24/12/42716329/jimmy-carter-the-39th-us-president-who-championed-human-rights-and-peace-in-the-middle-east-had-died">age of 100 Sunday.</a>
What Happened: The New York Stock Exchange, which is owned by the Intercontinental Exchange (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICE#NYSE">ICE</a>), confirmed Monday it <a href="https://www.benzinga.com/markets/24/12/42717748/will-markets-be-closed-for-former-president-jimmy-carters-funeral-heres-what-investors-should-know">will close markets </a>on Jan. 9 as part of President Joe Biden's declaration of a National Day of Mourning for Carter.
Carter served as the 39th president of the United States from 1977 to 1981 and was the oldest living president until his death Sunday.
"Jimmy Carter, with humble roots as a farmer and family man, devoted his life to public service and defending our freedom," NYSE Group President Lynn Martin said.
Martin said the NYSE will honor Carter's "lifetime of service" to the nation with the market closing on the National Day of Mourning and to coincide with his state funeral on Jan. 9 in Washington, D.C.
The U.S. flag above the NYSE will fly at half-staff throughout the mourning period.
The Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) will also close operations on Jan. 9 to honor Carter's life and legacy.
"We mourn the loss of President Carter and will be closing our U.S. markets during the National Day of Mourning to celebrate his life and honor his legacy," Nasdaq President Tal Cohen said.
Read Also<a href="https://www.benzinga.com/general/politics/24/10/41130171/jimmy-carter-at-100-5-things-you-didnt-know-about-the-rock-roll-president">: Jimmy Carter At 100: 5 Things You Didn&#8217;t Know About The Rock &amp; Roll President</a>
Why It's Important: The announcements from the NYSE and Nasdaq follow an American tradition of closing the stock markets after presidents die.
Major stock markets previously closed on Dec. 5, 2018 to coincide with the National Day of Mourning for former President George H.W. Bush. The markets were also closed on Jan. 2, 2007 to honor the life of former President Gerald R. Ford.
The major stock markets close to honor the lives of former presidents and have also closed due to natural disasters and national emergencies in the past.
Markets closed on April 9, 1968 for the National Day of Mourning for Martin Luther King Jr., the only non-president to receive the stock market honor. Markets are now closed every MLK Day, which is celebrated on the third Monday of January.
With the Jan. 9 closure, the stock markets will be closed three days in January: New Year's Day (Jan. 1), the National Day of Mourning (Jan. 9) and MLK Day (Jan. 20).
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42716729/jimmy-carter-to-receive-state-funeral-trump-calls-him-truly-a-good-man-biden-mourns-loss-of-extraordinary-leader">Jimmy Carter To Receive State Funeral: Trump Calls Him &#8216;Truly A Good Man,&#8217; Biden Mourns Loss Of &#8216;Extraordinary Leader&#8217;</a></li>
</ul>
Photo via Shutterstock.

Markets Will Close For President Jimmy Carter's State Funeral: What You Need To Know

Analysts' ratings for Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) over the last quarter vary from bullish to bearish, as provided by 21 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">14</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $85.86, along with a high estimate of $97.00 and a low estimate of $79.00. Witnessing a positive shift, the current average has risen by 3.93% from the previous average price target of $82.61.
<img src="https://www.benzinga.com/files/images/story/2024/1734717618_0_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nasdaq. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$91.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Richard Repetto</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$83.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Nasdaq. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Nasdaq's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nasdaq's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Get to Know Nasdaq Better</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Financial Insights: Nasdaq</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Nasdaq's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 31.08%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Nasdaq's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.79%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Nasdaq's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Nasdaq's debt-to-equity ratio stands notably higher than the industry average, reaching 0.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Nasdaq's Future

Keefe, Bruyette &amp; Woods analyst Kyle Voigt maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform and raises the price target from $86 to $91.

Keefe, Bruyette & Woods Maintains Outperform on Nasdaq, Raises Price Target to $91

On Friday, Nasdaq Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">opens on December 23</a>.
Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, the stock has increased around 8%, underperforming iShares Core S&amp;P Mid-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IJH#NYSE">IJH</a>).
The provider of DNA sequencing and array-based technologies has been in the news due to its controversial multi-billion dollar deal to acquire cancer test maker Grail Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">European Court Rules In Favor Of Illumina In Fight Against Probe Into Grail Deal, Asks Not To Pay $478M Fine</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png" alt="" class="wp-image-694387" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16125312/newplot-2-1-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Nearly four years after pitching for&nbsp;Grail,&nbsp;Illumina finally separated the&nbsp;<a target="_blank" href="https://www.benzinga.com/m-a/24/09/40688420/european-court-rules-in-favor-of-illumina-in-fight-against-probe-into-grail-deal-asks-not-to-pay-478" rel="noreferrer noopener">cancer blood test developer</a>.&nbsp;To expand its reach in single-cell analysis and&nbsp;multiomics research, Illumina <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39714633/illumina-buys-fluent-biosciences-to-gain-stronger-foothold-in-single-cell-analysis" rel="noreferrer noopener">acquired privately-held</a> Fluent BioSciences.
Also in March, activist investor&nbsp;Carl Icahn opted against pursuing a fresh challenge to Illumina&#8217;s board, which spares the U.S. gene sequencing company from facing its second proxy battle in consecutive years.&nbsp;
Previously, Icahn had expressed intentions to remove additional directors from Illumina&#8217;s board, attributing the company&#8217;s substantial market value decline and the ill-fated $7.1 billion Grail acquisition to mismanagement by the <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/03/37671511/gene-sequencing-firm-illumina-escapes-carl-icahns-second-proxy-battle-amid-grail-divestment-effort" rel="noreferrer noopener">existing board members</a>.&nbsp;
Most recently, Illumina reported third-quarter&nbsp;adjusted EPS of $1.14, beating the consensus of $0.88, with sales&nbsp;of $1.08 billion, almost in line with the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n41727185/illumina-reports-financial-results-for-third-quarter-of-fiscal-year-2024" rel="noreferrer noopener">consensus of $1.08 billion</a>.
&#8220;During the third quarter, the Illumina team delivered strong operating results, and revenue met our expectations,&#8221; said&nbsp;Jacob Thaysen, Chief Executive Officer.
&#8220;The near-term macroeconomic environment remains constrained, and we are slightly lowering our 2024 revenue guidance,&#8221; Thaysen added.
Price Action: ILMN stock is down 0.12% at $143.70 at the last check on Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42514376/whats-going-on-moderna-stock-on-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Moderna Stock On Monday?</a></li>
</ul>
Photo via Shutterstock

Health Care

General

GRAL

ILMN

What's Going On With Illumina Stock On Monday?

On Friday, Nasdaq Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) annual reconstitution of the Nasdaq-100 Index will become effective before the market opens <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42494812/annual-changes-to-the-nasdaq-100-index" rel="noreferrer noopener">on December 23</a>.
As a result, Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was&nbsp;removed&nbsp;<a target="_blank" href="https://www.benzinga.com/24/12/42495649/microstrategy-palantir-axon-added-to-nasdaq-100-super-micro-computer-moderna-illumina-exit-the-index" rel="noreferrer noopener">from the index</a>. Year to date, Moderna stock has plunged over 60%, with a 52-week low-high of $35.8-$170.47, as per data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Recently, Moderna and several other stocks witnessed a decline as Robert F. Kennedy Jr.'s, Donald Trump's nomination to lead the&nbsp;Department of&nbsp;Health and Human Services, is known to be against vaccines and has a track record of making false <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">claims about vaccines</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42045488/moderna-remains-confident-despite-political-concerns-over-vaccine-safety-and-hhs-nomination" rel="noreferrer noopener">Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png" alt="" class="wp-image-694341" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/16123322/newplot-1-3-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
The company has witnessed a decline in its only approved product, Spikevax, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40104375/moderna-stock-sinks-on-lowered-2024-outlook-cites-low-european-sales-competitive-rsv-vaccine-mark" rel="noreferrer noopener">the COVID-19 vaccine</a>.
However, Moderna witnessed some relief on higher third-quarter sales attributed to higher sales in the U.S. market following the earlier launch of the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41854205/modernas-q3-earnings-beat-overshadowed-by-vaccine-demand-slowdown-and-market-share-concerns-analysts-warn" rel="noreferrer noopener">updated COVID-19 vaccine</a>.
Moderna&nbsp;unveiled key updates at its annual R&amp;D Day in September, spotlighting its mRNA-based pipeline and <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40834547/moderna-outlines-post-covid-roadmap-cuts-research-budget-forecasts-2025-sales-below-expectations" rel="noreferrer noopener">revised financial plans</a>.
Faced with commercial challenges, Moderna is adopting a more selective approach to R&amp;D investments. The company anticipates maintaining substantial R&amp;D investment, especially in oncology and rare diseases, while pacing other expenditures.
Moderna is also facing several litigations, including the recently announced patent infringement lawsuit filed by Northwestern University. The lawsuit alleges that the pharmaceutical company used the university's lipid nanoparticle (LNP) technology without permission to develop&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41381861/moderna-hit-with-another-lawsuit-related-to-key-covid-19-vaccine-technology" rel="noreferrer noopener">its COVID-19 vaccines.</a>
GSK Plc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) also filed a lawsuit alleging that Moderna's mRNA vaccines infringe on&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41342286/gsk-sues-moderna-alleging-mrna-vaccine-patent-infringement" rel="noreferrer noopener">patents it developed</a>.
Price Action: MRNA stock is down 1.04% at $41.40 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42507816/taiwan-semiconductor-ceo-highlights-ai-powered-drones-next-gen-robots-as-growth-drivers" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor CEO Highlights AI-Powered Drones, Next-Gen Robots As Growth Drivers</a></li>
</ul>
Photo via <a href="https://commons.wikimedia.org/wiki/File:Moderna_COVID-19_vaccine_%282021%29_F.jpg">Wikimedia Commons</a>

Biotech

MRNA

What's Going On With Moderna Stock On Monday?

Barclays analyst Benjamin Budish maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Overweight and raises the price target from $87 to $97.

Barclays Maintains Overweight on Nasdaq, Raises Price Target to $97

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/12/05/final-trades-nasdaq-the-ibit-and-the-iau.html">Halftime Report Final Trades</a>,&#8221; Bill Baruch of Blue Line Capital picked iShares Bitcoin Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBIT#NYSE">IBIT</a>), saying this &#8220;<a href="https://www.benzinga.com/quote/IBIT">breakout is for real.&#8221;</a>
At the time of writing, Bitcoin price fell around 0.5% to trade at $98,660.13 on Friday.
Liz Young Thomas of SoFi named iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>) as her final trade.
Gold futures climbed 0.6% to trade at $2,663.40 an ounce this morning.
Don't forget to check out our<a href="https://www.benzinga.com/premarket/"> premarket coverage here</a>
Joshua Brown of Ritholtz Wealth Management said he likes Nasdaq, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>).
On Oct. 24, Nasdaq reported third-quarter revenue growth of 22% year-on-year to $1.15 billion, missing the analyst consensus estimate of $1.17 billion. The financial services company reported an adjusted EPS of 74 cents, which beat the analyst consensus estimate of 69 cents. The stock price slid after the print. Nasdaq&#8217;s Annualized Recurring Revenue (ARR) increased 31% year-over-year to $2.74 billion.
Nasdaq CEO Adena Friedman praised the "fourth consecutive quarter of double-digit Solutions growth <a href="https://www.benzinga.com/news/earnings/24/10/41517629/nasdaq-sees-recurring-revenue-soar-31-in-q3-solutions-rake-in-872m">with strong overall quarterly performance."</a>
Price Action:
<ul>
<li>iShares Bitcoin Trust slipped by 0.04% on Thursday.</li>
<li>Nasdaq shares rose by 0.5% to settle at $81.27 during Thursday's session.</li>
<li>iShares Gold Trust fell by 0.7% on Thursday.</li>
</ul>
Check This Out<a href="https://www.benzinga.com/24/12/42357598/dow-dips-more-than-200-points-ahead-of-jobs-report-investor-sentiment-declines-fear-greed-index-remains-in-greed-zone">: </a>
<ul>
<li><a href="https://www.benzinga.com/24/12/42357598/dow-dips-more-than-200-points-ahead-of-jobs-report-investor-sentiment-declines-fear-greed-index-remains-in-greed-zone">Dow Takes A Breather After Record Close, Dips Over 200 Points Ahead Of Jobs Report: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Topics

IBIT

Bitcoin 'Breakout Is For Real,' Analyst Says On CNBC's Final Trades

CNBC Halftime Report Final Trades: Nasdaq, iShares Bitcoin Trust, iShares Gold Trust Shares of the iShares Gold Trust

21 analysts have shared their evaluations of Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">13</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $85.0, with a high estimate of $93.00 and a low estimate of $79.00. This upward trend is apparent, with the current average reflecting a 5.88% increase from the previous average price target of $80.28.
<img src="https://www.benzinga.com/files/images/story/2024/1732557667_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Nasdaq among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Patrick O'Shaughnessy</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$82.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$84.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$88.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>Richard Repetto</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$88.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Announces</td>
<td>Hold</td>
<td>$83.00</td>
<td>-</td>
</tr>
<tr>
<td>Owen Lau</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$53.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Nasdaq. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Nasdaq compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Nasdaq's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nasdaq's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NDAQ/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Nasdaq analyst ratings.</a>
<h2>Unveiling the Story Behind Nasdaq</h2>
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
<h3>Nasdaq's Financial Performance</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Nasdaq showcased positive performance, achieving a revenue growth rate of 31.08% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Nasdaq's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 16.09%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Nasdaq's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.79%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Nasdaq's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.01%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Nasdaq's debt-to-equity ratio stands notably higher than the industry average, reaching 0.93. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Nasdaq

William Blair analyst Jeff Schmitt initiates coverage on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform rating.

Initiation

William Blair Initiates Coverage On Nasdaq with Outperform Rating

Novobanco and Nasdaq (NDAQ) announced the expansion of their technology partnership, which will see Novobanco expand its use of Nasdaq's Calypso pl...

Novobanco, Nasdaq expand technology partnership

The United Kingdom's leading stock exchange, London's FTSE 100, has hit a record intraday high as investors shift money into European equities. The...

U.K. Stock Exchange Hits Record High as Investors Pile into European Equities

Morgan Stanley analyst Michael Cyprys maintained a Buy rating on Nasdaq (NDAQ – Research Report) today and set a price target of $93.00. The compan...

Morgan Stanley Keeps Their Buy Rating on Nasdaq (NDAQ)

Asset manager Vanguard has been fined $106.41 million by the U.S. Securities and Exchange Commission (SEC) over disclosures concerning target date ...

Vanguard Fined $106 Million by SEC over Retirement Funds

The U.S. Supreme Court has upheld the law requiring China-based ByteDance to divest its ownership of TikTok by January 19 or face an effective ban ...

U.S. Supreme Court Upholds TikTok Ban

Stocks surged, clocking in their best week since the November presidential election and moving into the green year-to-date. The S&P 500 (SPX) was u...

3 Economic Events That Could Affect Your Portfolio This Week, January 20-24, 2025

Everything to Know about Macro and Markets Stocks surged, clocking in their best week since the November presidential election and moving into the ...

The Week That Was, The Week Ahead: Macro & Markets, January 19, 2025

Hedge funds around the world have charged their clients $1.8 trillion in fees since 1969 despite the fact that most of the active managers have und...

Hedge Funds Have Charged Nearly $2 Trillion in Fees While (Mostly) Underperforming the Market

Sugar prices have fallen to their lowest level in three years on news that India is restarting exports of the popular sweetener. India, the world's...

Sugar Prices Hit Three-Year Low

Cboe Global: Growth Catalysts, But Overpriced Entry

AAPL

CBOE

DJIA

GOOGL

Press Releases

Annual Changes to the Nasdaq-100 Index®

IPOs

Nasdaq Welcomed 171 IPOs in 2024

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date December 13, 2024

Nasdaq Announces the Closure of its U.S. Markets in Honor of a National Day of Mourning for Former President Jimmy Carter

Nasdaq to Hold Fourth Quarter and Full Year 2024 Investor Conference Call

Nasdaq Reports December 2024 Volumes and 4Q24 Statistics

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date December 31, 2024

Delisting of Securities of BIMI International Medical Inc.; The Dixie Group, Inc.; Clover Leaf Capital Corp.; Focus Impact BH3 Acquisition Company; Forza X1, Inc.; Vertex Energy, Inc; Slam Corp.; and HHG Capital Corporation from The Nasdaq Stock Market

Comments

Nasdaq

매도 수량

Nasdaq (NASDAQ:NDAQ) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌